First-line afatinib for the treatment of
EGFR tyrosine kinase inhibitors
NSCLC
afatinib
brain metastases
real-world
uncommon mutations
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
11
2018
accepted:
15
02
2019
entrez:
26
4
2019
pubmed:
26
4
2019
medline:
26
4
2019
Statut:
epublish
Résumé
Afatinib is an ErbB family blocker that is approved for the treatment of epidermal growth factor receptor (
Identifiants
pubmed: 31019567
doi: 10.1177/1758835919836374
pii: 10.1177_1758835919836374
pmc: PMC6466470
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1758835919836374Déclaration de conflit d'intérêts
Conflict of interest statement: KP has received personal fees from Boehringer Ingelheim, Clovis, Eli Lilly, Hanmi, Kyowa Hakko Kirin, Ono, Novartis, and Roche; and research funding from AstraZeneca. IO has received honoraria from Boehringer Ingelheim, AstraZeneca, Taiho Pharmaceuticals, Ono Pharmaceuticals, Merck Sharpe and Dohme, Lilly, Bristol-Myers Squibb, Chugai Pharma; and research funding from Boehringer Ingelheim. JY has received personal fees from Boehringer Ingelheim, AstraZeneca, Roche, Chugai, Eli Lilly, Clovis, Pfizer, Novartis, Merck Sharpe and Dohme, Astellas, Bayer, Innopharma, and Celgene; and research grants from Boehringer Ingelheim and AstraZeneca. DL reports no conflicts of interest.
Références
J Clin Oncol. 2018 Aug 1;36(22):2244-2250
pubmed: 29864379
Sci Transl Med. 2017 Nov 15;9(416):
pubmed: 29141884
Clin Cancer Res. 2011 Mar 1;17(5):1169-80
pubmed: 21248300
Lancet Oncol. 2017 Nov;18(11):1454-1466
pubmed: 28958502
J Clin Oncol. 2018 Aug 28;:JCO2018783118
pubmed: 30153097
Asian Pac J Cancer Prev. 2012;13(3):909-14
pubmed: 22631670
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
BMC Cancer. 2018 Dec 24;18(1):1288
pubmed: 30583726
Ann Oncol. 2017 Oct 01;28(10):2443-2450
pubmed: 28945850
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Target Oncol. 2018 Jun;13(3):269-285
pubmed: 29700687
Oncotarget. 2017 Jan 3;8(1):1343-1353
pubmed: 27935868
Oncotarget. 2017 Jul 26;8(52):90430-90443
pubmed: 29163842
J Clin Oncol. 2017 Apr 20;35(12):1288-1296
pubmed: 28221867
Clin Cancer Res. 2016 Oct 15;22(20):5130-5140
pubmed: 27435396
Clin Cancer Res. 2015 Dec 1;21(23):5305-13
pubmed: 26206867
Lung Cancer. 2017 Jul;109:137-144
pubmed: 28577943
Lung Cancer. 2017 Aug;110:56-62
pubmed: 28676220
Lancet Oncol. 2016 May;17(5):577-89
pubmed: 27083334
Acta Pharmacol Sin. 2017 Feb;38(2):233-240
pubmed: 27840411
Clin Cancer Res. 2013 Apr 15;19(8):2240-7
pubmed: 23470965
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
BMC Pharmacol Toxicol. 2017 Dec 13;18(1):82
pubmed: 29237484
Oncotarget. 2017 Feb 21;8(8):13304-13311
pubmed: 28076323
J Clin Oncol. 2018 Mar 20;36(9):841-849
pubmed: 28841389
Oncol Lett. 2017 Dec;14(6):7589-7596
pubmed: 29344206
Target Oncol. 2019 Feb;14(1):75-83
pubmed: 30539501
N Engl J Med. 2015 Apr 30;372(18):1689-99
pubmed: 25923549
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Cancer Sci. 2016 Sep;107(9):1179-86
pubmed: 27323238
J Clin Oncol. 2005 Sep 1;23(25):6207-19
pubmed: 16135488
Oncotarget. 2018 May 4;9(34):23749-23760
pubmed: 29805772
Ann Oncol. 2016 Nov;27(11):2103-2110
pubmed: 27601237
Lancet Oncol. 2015 Jul;16(7):830-8
pubmed: 26051236
Lancet Oncol. 2011 Aug;12(8):735-42
pubmed: 21783417
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
Front Oncol. 2014 Sep 16;4:238
pubmed: 25279350
Ther Adv Med Oncol. 2018 Jan 22;10:1758834017753338
pubmed: 29383041
Ann Am Thorac Soc. 2014 Feb;11 Suppl 2:S99-104
pubmed: 24559028
Lung Cancer. 2019 Sep;135:175-180
pubmed: 31446992
Ann Oncol. 2015 Sep;26(9):1883-1889
pubmed: 26105600
Clin Lung Cancer. 2018 Jul;19(4):e465-e479
pubmed: 29653820
Lancet Oncol. 2014 Feb;15(2):213-22
pubmed: 24439929
Oncotarget. 2018 Feb 04;9(36):24237-24247
pubmed: 29849936
Int J Cancer. 2019 Jun 1;144(11):2887-2896
pubmed: 30485437
Cancer Res Treat. 2019 Apr;51(2):502-509
pubmed: 29898592
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059439
Oncotarget. 2017 Jul 12;8(40):68123-68130
pubmed: 28978102
Sci Transl Med. 2011 Mar 23;3(75):75ra26
pubmed: 21430269
Chemother Res Pract. 2014;2014:856156
pubmed: 25548673
Oncotarget. 2016 Mar 15;7(11):12404-13
pubmed: 26862733
J Thorac Oncol. 2014 Feb;9(2):189-94
pubmed: 24419415
Anticancer Res. 2017 Aug;37(8):4177-4182
pubmed: 28739703
Ann Oncol. 2017 Feb 1;28(2):270-277
pubmed: 28426106
Oncol Res. 2018 Aug 23;26(7):1031-1036
pubmed: 29321093
Cancer. 2018 Jan 1;124(1):105-109
pubmed: 28940498
Value Health. 2017 Jul - Aug;20(7):866-875
pubmed: 28712615
Clin Cancer Res. 2018 Jul 1;24(13):3097-3107
pubmed: 29506987
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Future Oncol. 2018 Nov;14(27):2861-2874
pubmed: 30336693
J Thorac Oncol. 2016 Mar;11(3):380-90
pubmed: 26823294
JAMA Oncol. 2018 Nov 1;4(11):1527-1534
pubmed: 30073261
Future Oncol. 2018 May;14(11):1117-1132
pubmed: 29336166
Expert Rev Anticancer Ther. 2018 Jan;18(1):81-89
pubmed: 29172778
Oncotarget. 2017 Jun 27;8(57):97602-97612
pubmed: 29228636
N Engl J Med. 2016 Dec 8;375(23):2293-2297
pubmed: 27959688